Skip to main content
Fig. 3 | Molecular Cancer

Fig. 3

From: A bedside to bench study of anti-PD-1, anti-CD40, and anti-CSF1R indicates that more is not necessarily better

Fig. 3

Associations between clinical benefit and changes in human cell populations or individual markers. A. Ratio of percentages of myeloid DCs, CD8 T-cells, memory B-cells and classical monocytes at C1D2 over C1D1 or C2D1 over C1D1. B. Ratio of average expression of CD40 or CD86 at C2D1 over C1D1 in indicated cell types in patients with progressive disease versus stable/partial response and in short-term (< 200 days) versus prolonged (> 200 days) trial duration

Back to article page

Molecular Cancer

ISSN: 1476-4598